XLO - Xilio Development - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

XLO is currently covered by 1 analysts with an average price target of $4.93. This is a potential upside of $4.23 (604.29%) from yesterday's end of day stock price of $0.7.

Xilio Development's activity chart (see below) currently has 4 price targets and 5 ratings on display. The stock rating distribution of XLO is 100% BUY.

Stock Analyst Price Targets - Review

Highest price target for XLO is $4, Lowest price target is $4, average price target is $4.

Most recent stock forecast was given by DANE LEONE from RAYMOND JAMES on 08-Nov-2024. First documented stock forecast 16-Nov-2021.

Best performing analysts who are covering XLO - Xilio Development:

Michael Ulz Dane Leone Matthew Barcus

Currently out of the existing stock ratings of XLO, 1 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$4

$2.93 (273.83%)

$31

7 months ago
(08-Nov-2024)

0/2 (0%)

$3.01 (304.04%)

Buy

$7

$5.93 (554.21%)

$7

2 years 9 days ago
(30-May-2023)

0/3 (0%)

$3.95 (129.51%)

Buy

$10

$8.86 (777.19%)

2 years 4 months 12 days ago
(27-Jan-2023)

0/2 (0%)

$5.72 (133.64%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is XLO (Xilio Development) average time for price targets to be met?

On average it took 0 days on average for the stock forecasts to be realized with a an average price target met ratio 0

Which analyst has the current highest performing score on XLO (Xilio Development) with a proven track record?

MICHAEL ULZ

Which analyst has the current lower performing score on XLO (Xilio Development) with a proven track record?

MATTHEW BARCUS

Which analyst has the most public recommendations on XLO (Xilio Development)?

Michael Ulz works at BAIRD and has 12 price targets and 6 ratings on XLO

Which analyst is the currently most bullish on XLO (Xilio Development)?

Michael Ulz with highest potential upside - $8.86

Which analyst is the currently most reserved on XLO (Xilio Development)?

Dane Leone with lowest potential downside - $2.93

Xilio Development in the News

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results

Updated Phase 2 data to be presented at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, in combination with atezolizumab in patients with metastatic microsatellite stable colorectal cancer (MSS CRC) Advancing multiple masked T cell engager programs utilizing Xilio’snovel ATACR and SEECR formats, with first development candidates anticipated in second half of 2025 WALTHAM, Mass., May...

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., May 02, 2025 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective May 1, 2025, the company granted a non-qualified stock option to purchase 5,000 shares of its common stock to one new employee under...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?